Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Stefan S Bielack, Sigbjørn Smeland, Jeremy S Whelan, Neyssa Marina, Gordana Jovic, Jane M Hook, Mark D Krailo, Mark Gebhardt, Zsuzsanna Pápai, James Meyer, Helen Nadel, R Lor Randall, Claudia Deffenbaugh, Rajaram Nagarajan, Bernadette Brennan, G Douglas Letson, Lisa A Teot, Allen Goorin, Daniel Baumhoer, Leo KagerMathias Werner, Ching C Lau, Kirsten Sundby Hall, Hans Gelderblom, Paul Meyers, Richard Gorlick, Reinhard Windhager, Knut Helmke, Mikael Eriksson, Peter M Hoogerbrugge, Paula Schomberg, Per-Ulf Tunn, Thomas Kühne, Heribert Jürgens, Henk van den Berg, Tom Böhling, Susan Picton, Marleen Renard, Peter Reichardt, Joachim Gerss, Trude Butterfass-Bahloul, Carol Morris, Pancras C W Hogendoorn, Beatrice Seddon, Gabriele Calaminus, Maria Michelagnoli, Catharina Dhooge, Matthew R Sydes, Mark Bernstein

Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

44 Nedladdningar (Pure)

Fingeravtryck

Fördjupa i forskningsämnen för ”Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial”. Tillsammans bildar de ett unikt fingeravtryck.

Medicin och livsvetenskap